The Italian Tamoxifen Prevention Trial

B Bonanni, Bonanni B, U Veronesi, Veronesi U
Disease markers · 1999 · vol. 15(1-3) , pp. 199–200 · doi:10.1155/1999/836912 · PMID:10644176 · PMC3851122
RCT OA: gold CC-BY-4.0
📄 Open PDF View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-09-28 ⓘ

The provided source contains only the title of the Italian Tamoxifen Prevention Trial without an abstract or text, making it impossible to summarize the study's specific findings or relevance to endometriosis and adenomyosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

MeSH descriptors

Anticarcinogenic Agents Antineoplastic Agents, Hormonal Breast Neoplasms Tamoxifen Adult Aged Anticarcinogenic Agents Anticarcinogenic Agents Antineoplastic Agents, Hormonal Antineoplastic Agents, Hormonal Breast Neoplasms Breast Neoplasms Cohort Studies Double-Blind Method Female Follow-Up Studies Hormone Replacement Therapy Humans Hypertriglyceridemia Hypertriglyceridemia

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-10-18T09:30:06.152893+00:00
pubmed
last seen: 2026-10-08T20:59:14.592962+00:00
unpaywall
last seen: 2026-05-21T05:10:58.409756+00:00
License: CC-BY-4.0